**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

|  |  |
| --- | --- |
| (Check One):  | ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
|   |   |
|   | For Period Ended: **December 31, 2022** |
|   | ☐ Transition Report on Form 10-K |
|   | ☐ Transition Report on Form 20-F |
|   | ☐ Transition Report on Form 11-K |
|   | ☐ Transition Report on Form 10-Q |
|   |   |
|   | For the Transition Period Ended: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**SHL TELEMEDICINE LTD.**

Full Name of Registrant:

Former Name if Applicable:

**90 Yigal Alon Street**

Address of Principal Executive Office (Street and Number):

**Tel Aviv 67891, Israel**

City, State and Zip Code

|  |
| --- |
|   |

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

|  |  |  |
| --- | --- | --- |
|   | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|   |   |   |
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|   |   |   |
|   | (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

SHL Telemedicine Ltd. (the “**Company**”) is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “**2022 Annual Report on Form 20-F**”) by the prescribed filing date without unreasonable effort or expense because work on the preparation of the Company’s Registration Statement on Form 20-F in connection with the its registration under the U.S. Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), and listing of its American Depositary Shares on the NASDAQ Capital Market, which was completed on April 3, 2023, significantly delayed the preparation of the Company’s year-end financial reporting process and the finalization of its 2022 fiscal year financial statements and 2022 Annual Report on Form 20-F. The Company currently anticipates that it will file its 2022 Annual Report on Form 20-F no later than the fifteenth calendar day following the prescribed due date.

**PART IV — OTHER INFORMATION**

|  |  |
| --- | --- |
| (1) | Name and telephone number of person to contact in regard to this notification |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | Amir Hai |   | +972 |   | (3) 561-2212 |
|   | (Name) |   | (Area Code) |   | (Telephone Number) |

|  |  |
| --- | --- |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). |
|   |   |
|   | ☒ Yes ☐ No |
|   |   |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
|   |   |
|   | ☐ Yes ☒ No |

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

|  |
| --- |
|   |

**Forward-Looking Statements**

This Notification on Form 12b-25 contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the Exchange Act. All statements, other than statements of historical facts, are forward-looking statements, including, the Company’s anticipation with respect to changes in its results of operations from prior periods and the Company’s expectations as to the timing of filing its 2022 Annual Report on Form 20-F. Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. “Key Information—Risk Factors” contained in the Company’s Registration Statement on Form 20-F filed with the U.S. Securities Exchange Commission (the “**SEC**”) on March 28, 2023 and in its subsequent filings and submissions with the SEC, including, but not limited to, the Company’s ability to complete the preparation of its year-end financial statements and preparation and filing of its 2022 Annual Report on Form 20-F within the fifteen-day period provided in the SEC’s rules; the Company’s ability to operate and comply with the complex and evolving regulations in the highly regulated healthcare industry; continued development, consumer acceptance and market adoption in the relatively new, unproven and volatile and rapidly changing telehealth market; the Company’s ability to develop and introduce new products and solutions and enhancements to existing ones; the significant and increasing levels of competition in the telemedicine market; the impacts of COVID-19 and future pandemics and epidemics; the Company’s ability to continue to attract and retain key employees and personal in the highly competitive healthcare industry; the loss or breach of the Company’s proprietary rights and data security and privacy risks; political, judicial, legal, economic and military conditions in Israel and the surrounding region; global economic and financial market conditions and the Company’s ability to adapt to and comply with the different business and market factors, conditions, requirements and laws and regulations in the various countries in which the Company operates internationally; currency fluctuations; labor disputes; the Company’s ability to manage growth and integrate acquired businesses and expanding operations; the Company’s ability to obtain adequate levels of insurance to cover potential losses; the Company’s dependence on key suppliers and sub-contractors and other third parties; and other matters and risks not yet known to the Company or not currently considered material by it. You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to the Company, or persons acting on its behalf, are qualified in their entirety by these cautionary statements. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements.

**SHL Telemedicine ltd.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  |  |
| --- | --- | --- |
| Date: April 28, 2023 | By | */s/ Amir Hai* |
|   |   | Amir Hai |
|   |   | Chief Financial Officer |